Fig. 4From: Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analysesRelapse-free survival probability according to the AJCC response in each breast cancer subgroup: a luminal A type, b luminal B type, c HER2-enriched type, and d triple-negative breast cancer typeBack to article page